Favipravir induced Acute generalized exanthematous pustulosis: 1st case reported
Source- Thienvibul C, Vachiramon V, Chanprapaph K. Five-Year Retrospective Review of Acute Generalized
Exanthematous Pustulosis. Dermatol Res Pract. 2015;2015:260928. doi: 10.1155/2015/260928. Epub 2015 Dec 10. PMID: 26783390; PMCID: PMC4689982.
Acute generalized exanthematous pustulosis (AGEP) post favipravir for COVID-19: 1st case reported
Favipravir is a synthetic prodrug initially used against influenza A and B viruses. It has now come into focus due to its use against SARS-COV2 virus. Cutaneous adverse events to this drug are rare with pruritus and eczema being the major adverse effects. AGEP has been reported in COVID-19 patients mostly due to hydroxychloroquine and β-lactam antibiotics. First case report of AGEP secondary to favipiravir was reported in the Journal of Cosmetic Dermatology.
A 20-year-old male was admitted for fever and rapid onset, mildly itchy erythematous, edematous plaques involving the trunks and proximal extremities with grouped pustular lesions on an edematous-erythematous background. Patient was diagnosed with COVID-19 infection 16 days back and favipiravir monotherapy was administered with a loading dose of 1600 mg bid, followed by 600 mg bid daily for 7 days with complete resolution of symptoms. Patient had not taken any drugs other than favipiravir in the last 8 weeks.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.